Mellen PL, Obeid A, Wibbelsman TD, et al. - Researchers conducted this retrospective cohort study to assess outcomes after switching from intravitreal aflibercept (IVA) to intravitreal ranibizumab (IVR) in diabetic macular edema (DME). Eyes switched from IVA to IVR for treating DME were involved. Data were obtained from three visits before to three visits post-switch. By switching from aflibercept to ranibizumab, the authors observed transient worsening of macular edema in eyes treated for DME.